ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0759

Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry
Abstract Number: 1158

Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Abstract Number: 1211

Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population
Abstract Number: 1612

Design and Validation of a Comparator for Randomized Controlled Trials of a Digital Cognitive Behavioral Therapy
Abstract Number: 0591

Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain
Abstract Number: 0262

Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients
Abstract Number: 0423

Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Abstract Number: 1843

Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning
Abstract Number: 0024

Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy
Abstract Number: 0261

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results
Abstract Number: 1144

Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years
Abstract Number: 2253

Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Abstract Number: 2328

Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Abstract Number: 0596

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].